Previous Close | 37.52 |
Open | 37.40 |
Bid | 37.30 x 800 |
Ask | 0.00 x 900 |
Day's Range | 36.44 - 37.96 |
52 Week Range | 27.21 - 67.49 |
Volume | |
Avg. Volume | 367,514 |
Market Cap | 1.317B |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.60 |
Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SILK
SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market study, called ROADSTER 3, will fulfill the U.S. Food and Drug Administration’s (FDA) condition of approval for the recent expansion of labeling for the ENROUTE® Transca
Insiders who bought US$103k worth of Silk Road Medical, Inc ( NASDAQ:SILK ) stock in the last year have seen some of...
SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI’s TCAR Surveillance Pr